Skip to content
2000
Volume 22, Issue 1
  • ISSN: 1875-6921
  • E-ISSN: 1875-6913

Abstract

Introduction

This case report presents a 26-year-old male with complaints of obesity, hepatomegaly, and early-stage neuropsychiatric symptoms, including obsessive-compulsive disorder (OCD) and obsessive imagination. The investigation aimed to identify major gene mutations contributing to both neuropsychiatric disorders and abnormalities in lipid metabolism.

Case Presentation

The subject had marked dyslipidemia with an increased LDL-C (163 mg/dL), total cholesterol (236 mg/dL), and borderline triglycerides (172 mg/dL) levels. Moreover, the patient had Grade 1 fatty liver and splenomegaly. Neurological symptoms like panic attacks, obsessive-compulsive disorder, and obsessive imagination have been associated with mutations in LRP8, FLG, and MT-CYB, which points to a possible disruption in neuronal signalling pathways.

Conclusion

Obesity is the primary cause of hepatomegaly and is also suggested to be inversely involved in mental health. Our results show a complex interplay between lipid metabolism, liver dysfunction, and neuropsychiatric disorders. Personalised therapeutic strategies, focusing on both the diagnosis and the interactions between the results, are a necessary factor for future medical care and treatment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cppm/10.2174/0118756921380625250806101059
2025-08-18
2026-01-18

  • From This Site

    /content/journals/cppm/10.2174/0118756921380625250806101059
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LinX. LiH. Obesity: Epidemiology, pathophysiology, and therapeutics.Front. Endocrinol.20211270697810.3389/fendo.2021.706978 34552557
     [Google Scholar]
  2. AnsariS. HaboubiH. HaboubiN. Adult obesity complications: Challenges and clinical impact.Ther. Adv. Endocrinol. Metab.202011204201882093495510.1177/2042018820934955 32612803
     [Google Scholar]
  3. BlüherM. n overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes Diabetes Obes Metab202527S2319.(Suppl. 2)10.1111/dom.1626340069923
    [Google Scholar]
  4. FruhS.M. Obesity.J. Am. Assoc. Nurse Pract.201729S1S3S1410.1002/2327‑6924.12510 29024553
     [Google Scholar]
  5. ArulJothiKN WhitthallRA FutemaM Molecular analysis of the LDLR gene in coronary artery disease patients from the Indian population.Clin. Biochem.201649966967410.1016/j.clinbiochem.2016.02.009 26927322
     [Google Scholar]
  6. ArulJothiKN Suruthi Abirami B, Devi A. Genetic spectrum of low density lipoprotein receptor gene variations in South Indian population.Clin. Chim. Acta2018478283610.1016/j.cca.2017.12.024 29269200
     [Google Scholar]
  7. VaeziZ. AminiA. Familial Hypercholesterolemia.Treasure Island, FLStatPearls2023
     [Google Scholar]
  8. NoharaA. TadaH. OguraM. Homozygous Familial Hypercholesterolemia.J. Atheroscler. Thromb.202128766567810.5551/jat.RV17050 33867421
     [Google Scholar]
  9. TrinderM. LiX. DeCastroM.L. Risk of premature atherosclerotic disease in patients with monogenic versus polygenic familial hypercholesterolemia J Am Coll Cardiol20197445122210.1016/j.jacc.2019.05.043 31345425
     [Google Scholar]
  10. Harada-ShibaM. What arteries are affected in familial hypercholesterolemia?J. Atheroscler. Thromb.201926121041104210.5551/jat.ED121 31645527
     [Google Scholar]
  11. MaraisA.D. Familial hypercholesterolaemia.Clin. Biochem. Rev.20042514968 18516203
     [Google Scholar]
  12. ArulJothiKN Kumaran K, Abirami S, Kirubakaran R, Devi A. Exploring the LDL-cholesterol raising SNPs gene scores for improved screening of polygenic familial hypercholesterolemia in Indian population: Pilot study.Gene Rep.20233010173510.1016/j.genrep.2022.101735
     [Google Scholar]
  13. McGowanM.P. Hosseini DehkordiS.H. MoriartyP.M. DuellP.B. Diagnosis and treatment of heterozygous familial hypercholesterolemia.J. Am. Heart Assoc.2019824e01322510.1161/JAHA.119.013225 31838973
     [Google Scholar]
  14. FutemaM. Taylor-BeadlingA. WilliamsM. HumphriesS.E. Genetic testing for familial hypercholesterolemia—past, present, and future.J. Lipid Res.20216210013910.1016/j.jlr.2021.100139 34666015
     [Google Scholar]
  15. Vallejo-VazA.J. StevensC.A.T. LyonsA.R.M. Global perspective of familial hypercholesterolaemia: A cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).Lancet2021398103121713172510.1016/S0140‑6736(21)01122‑3 34506743
     [Google Scholar]
  16. AjufoE. RaderD.J. New therapeutic approaches for familial hypercholesterolemia.Annu. Rev. Med.201869111313110.1146/annurev‑med‑051215‑030943 29414257
     [Google Scholar]
  17. DandgeyS. PattenE. Psychological considerations for the holistic management of obesity.Clin. Med202323431832210.7861/clinmed.2023‑0146 37524420
     [Google Scholar]
  18. SteptoeA FrankP Obesity and psychological distress.Philos Trans R Soc Lond B Biol Sci 202337818882022022510.1098/rstb.2022.022537661745
    [Google Scholar]
  19. BjörkhemI. LeoniV. MeaneyS. Genetic connections between neurological disorders and cholesterol metabolism.J. Lipid Res.20105192489250310.1194/jlr.R006338 20466796
     [Google Scholar]
  20. JiangJ. ChenH. WangL. (Gene expression analysis of familial hypercholesterolemia).Mol. Biol. (Mosk.)201448118519210.7868/S0026898414010042 25842839
     [Google Scholar]
  21. BiriaM. BancaP. HealyM.P. Cortical glutamate and GABA are related to compulsive behaviour in individuals with obsessive compulsive disorder and healthy controls.Nat. Commun.2023141332410.1038/s41467‑023‑38695‑z 37369695
     [Google Scholar]
  22. SteinD.J. CostaD.L.C. LochnerC. Author Correction: Obsessive–compulsive disorder.Nat. Rev. Dis. Primers20241017910.1038/s41572‑024‑00569‑z 39414819
     [Google Scholar]
  23. AdhikaryD. BarmanS. RanjanR. StoneH. A systematic review of major cardiovascular risk factors: A growing global health concern.Cureus20221410e3011910.7759/cureus.30119 36381818
     [Google Scholar]
  24. BakourH.A. Hussain TimrazJ. Bin SaddiqB.W. Familial hypercholesterolemia: A comprehensive review of advances in treatment strategies and the role of patient beliefs.Cureus2025171e7803210.7759/cureus.78032 40013201
     [Google Scholar]
  25. GrishamJ.R. FullanaM.A. Mataix-ColsD. MoffittT.E. CaspiA. PoultonR. Risk factors prospectively associated with adult obsessive–compulsive symptom dimensions and obsessive–compulsive disorder.Psychol. Med.201141122495250610.1017/S0033291711000894 21672296
     [Google Scholar]
  26. HutchinsonL. DeVitaV.T. The era of personalized medicine: Back to basics.Nat. Clin. Pract. Oncol.2008511623310.1038/ncponc1253 18957968
     [Google Scholar]
  27. SeremetT. Di DomizioJ. GirardinA. Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases.Nat. Commun.20241511068810.1038/s41467‑024‑54559‑6 39695162
     [Google Scholar]
  28. HovenM. MulderT. DenysD. van HolstR.J. LuigjesJ. Lower confidence and increased error sensitivity in OCD patients while learning under volatility.Transl. Psychiatry202414137010.1038/s41398‑024‑03042‑3 39266521
     [Google Scholar]
  29. PillaiK.K.B. ShahS.A.V. ReddyL.L. AshavaidT.F. VishwanathanS. Targeted exome sequencing in South Indian patients with Familial hypercholesterolemia.Clin. Chim. Acta2022527475510.1016/j.cca.2021.12.022 34998859
     [Google Scholar]
  30. WangD. LiuB. XiongT. YuW. SheQ. Investigation of the underlying genes and mechanism of familial hypercholesterolemia through bioinformatics analysis.BMC Cardiovasc. Disord.202020141910.1186/s12872‑020‑01701‑z 32938406
     [Google Scholar]
  31. OlmastroniE. GazzottiM. ArcaM. Twelve variants polygenic score for low‐density lipoprotein cholesterol distribution in a large cohort of patients with clinically diagnosed familial hypercholesterolemia with or without causative mutations.J. Am. Heart Assoc.2022117e02366810.1161/JAHA.121.023668 35322671
     [Google Scholar]
  32. FutemaM. ShahS. CooperJ.A. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries.Clin. Chem.201561123123810.1373/clinchem.2014.231365 25414277
     [Google Scholar]
  33. KhojahA. MorganG. KadakiaA. Klein-GitelmanM.S. PachmanL.M. Dyslipidemia in juvenile dermatomyositis.Sci. Rep.20241412652810.1038/s41598‑024‑77985‑4 39489760
     [Google Scholar]
  34. SongY. KuroseA. LiR. Ablation of selenbp1 alters lipid metabolism via the pparα pathway in mouse kidney.Int. J. Mol. Sci.20212210533410.3390/ijms22105334 34069420
     [Google Scholar]
  35. WangL. YangZ. HeX. Mitochondrial protein dysfunction in pathogenesis of neurological diseases.Front. Mol. Neurosci.20221597448010.3389/fnmol.2022.974480 36157077
     [Google Scholar]
  36. RiddellD.R. VinogradovD.V. StannardA.K. ChadwickN. OwenJ.S. Identification and characterization of LRP8 (apoER2) in human blood platelets.J. Lipid Res.199940101925193010.1016/S0022‑2275(20)34910‑5 10508213
     [Google Scholar]
  37. PassarellaD. CiampiS. Di LibertoV. Low-Density lipoprotein receptor-related protein 8 at the crossroad between cancer and neurodegeneration.Int. J. Mol. Sci.20222316892110.3390/ijms23168921 36012187
     [Google Scholar]
  38. RamananV.K. WangX. PrzybelskiS.A. Variants in PPP2R2B and IGF2BP3 are associated with higher tau deposition.Brain Commun.202022fcaa15910.1093/braincomms/fcaa159 33426524
     [Google Scholar]
  39. IqbalZ. BashirB. FerdousiM. Lipids and peripheral neuropathy.Curr. Opin. Lipidol.202132424925710.1097/MOL.0000000000000770 34101657
     [Google Scholar]
  40. O’malleyM.A. Constructive personalized medicine: The potential integration of synthetic biology and personalized medicine.Curr. Pharmacogenomics Person. Med.20119317718310.2174/187569211796957593
     [Google Scholar]
  41. KheraA.V. RaderD.J. Discovery and validation of new molecular targets in treating dyslipidemia: The role of human genetics.Trends Cardiovasc. Med.200919619520110.1016/j.tcm.2009.12.003 20211435
     [Google Scholar]
  42. KornevaV. KuznetsovaT. JuliusU. The role of cumulative ldl cholesterol in cardiovascular disease development in patients with familial hypercholesterolemia.J. Pers. Med.20221217110.3390/jpm12010071 35055385
     [Google Scholar]
  43. PihlstrømL. WiethoffS. HouldenH. Genetics of neurodegenerative diseases: An overview In: Kovacs GG, Alafuzoff I, EdsNeuropathology.201830932310.1016/B978‑0‑12‑802395‑2.00022‑5
     [Google Scholar]
  44. SegalY. GunturuS. Psychological Issues Associated With Obesity.Treasure Island, FLStatPearls2025
     [Google Scholar]
  45. Elmaleh-SachsA. SchwartzJ.L. BramanteC.T. NicklasJ.M. GudzuneK.A. JayM. Obesity Management in Adults.JAMA2023330202000201510.1001/jama.2023.19897 38015216
     [Google Scholar]
  46. MoralesA. GoehringerJ. SanoudouD. Evolving cardiovascular genetic counseling needs in the era of precision medicine.Front. Cardiovasc. Med.202310116102910.3389/fcvm.2023.1161029 37424912
     [Google Scholar]
  47. MckayD. OCD or not OCD? A critical evaluation of the obsessive compulsive related disorders.Curr. Psychiatry Rev.201410428428810.2174/1573400510666140619224455
     [Google Scholar]
  48. Chacón-CamachoO.F. Pozo-MolinaG. Méndez-CataláC.F. Reyes-RealiJ. Méndez-CruzR. ZentenoJ.C. Familial hypercholesterolemia: Update and review.Endocr. Metab. Immune Disord. Drug Targets202222219821110.2174/1871530321666210208212148 33563162
     [Google Scholar]
  49. SetiaN. SaxenaR. AroraA. VermaI.C. Spectrum of mutations in homozygous familial hypercholesterolemia in India, with four novel mutations.Atherosclerosis2016255313610.1016/j.atherosclerosis.2016.10.028 27816806
     [Google Scholar]
  50. TallisF. The neuropsychology of obsessive—compulsive disorder: A review and consideration of clinical implications.Br. J. Clin. Psychol.199736132010.1111/j.2044‑8260.1997.tb01226.x 9051274
     [Google Scholar]
  51. LuoY. HouY. ZhaoW. YangB. Recent progress in gene therapy for familial hypercholesterolemia treatment.iScience202427911064110.1016/j.isci.2024.110641 39262805
     [Google Scholar]
  52. AtharM. ToonsiM. AbduljaleelZ. Novel LDLR Variant in Familial Hypercholesterolemia: NGS-Based Identification, In silico Characterization, and Pharmacogenetic Insights.Life2023137154210.3390/life13071542 37511917
     [Google Scholar]
  53. YangD. WangX. ZhangL. Lipid metabolism and storage in neuroglia: Role in brain development and neurodegenerative diseases.Cell Biosci.202212110610.1186/s13578‑022‑00828‑0 35831869
     [Google Scholar]
  54. KasianthanK. KumarJ.S. Gene expression analysis reveals clinically significant genes associated with familial hypercholesterolemia and atherosclerosis.Gene Expr.2025241102010.14218/GE.2023.00184
     [Google Scholar]
  55. Van CraeyveldE. JacobsF. GordtsS.C. De GeestB. Gene therapy for familial hypercholesterolemia.Curr. Pharm. Des.201117242575259110.2174/138161211797247550 21774774
     [Google Scholar]
  56. Gouni-BertholdI. BertholdH. Familial hypercholesterolemia: Etiology, diagnosis and new treatment options.Curr. Pharm. Des.201420406220622910.2174/1381612820666140620125213 24953396
     [Google Scholar]
  57. LiY. YangX. PlummerR. Human pluripotent stem cell-derived hepatocyte-like cells and organoids for liver disease and therapy.Int. J. Mol. Sci.202122191047110.3390/ijms221910471 34638810
     [Google Scholar]
  58. Al-AllafF.A. CoutelleC. WaddingtonS.N. DavidA.L. HarbottleR. ThemisM. LDLR-Gene therapy for familial hypercholesterolaemia: Problems, progress, and perspectives.Int. Arch. Med.2010313610.1186/1755‑7682‑3‑36 21144047
     [Google Scholar]
/content/journals/cppm/10.2174/0118756921380625250806101059
Loading
Hypercholesterolemia at the Crossroads of Lipid Metabolism, Hepatomegaly, and Neuropsychiatric Dysfunction
Curr. Pharm. and. Per. Med. 22, E18756921380625 (2025); https://doi.org/10.2174/0118756921380625250806101059
/content/journals/cppm/10.2174/0118756921380625250806101059
/content/journals/cppm/10.2174/0118756921380625250806101059
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Case Report
Keyword(s): hepatomegaly; lipid metabolism; neuropsychiatric dysfunction; obesity; OCD; Personalised medicine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test